Silence Therapeutics plc
SLN
$7.35
$0.456.52%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 34.00K | 159.00K | 224.00K | 142.00K | 25.31M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.00K | 159.00K | 224.00K | 142.00K | 25.31M |
| Cost of Revenue | 12.00K | 64.00K | 85.00K | 54.00K | 2.04M |
| Gross Profit | 22.00K | 95.00K | 139.00K | 88.00K | 23.27M |
| SG&A Expenses | 3.73M | 5.80M | 5.13M | 7.68M | 5.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.67M | 23.82M | 20.49M | 25.87M | 25.63M |
| Operating Income | -12.63M | -23.66M | -20.27M | -25.73M | -328.00K |
| Income Before Tax | -11.77M | -20.96M | -27.34M | -28.53M | 12.63M |
| Income Tax Expenses | 0.00 | 1.00K | 10.00K | -- | 324.00K |
| Earnings from Continuing Operations | -11.77M | -20.96M | -27.35M | -28.53M | 12.30M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.77M | -20.96M | -27.35M | -28.53M | 12.30M |
| EBIT | -12.63M | -23.66M | -20.27M | -25.73M | -328.00K |
| EBITDA | -12.52M | -23.51M | -20.12M | -25.59M | -188.00K |
| EPS Basic | -0.75 | -1.33 | -1.74 | -1.81 | 0.78 |
| Normalized Basic EPS | -0.16 | -0.28 | -0.34 | -0.38 | 0.17 |
| EPS Diluted | -0.75 | -1.33 | -1.74 | -1.81 | 0.78 |
| Normalized Diluted EPS | -0.16 | -0.28 | -0.34 | -0.38 | 0.17 |
| Average Basic Shares Outstanding | 47.23M | 47.23M | 47.23M | 47.23M | 47.23M |
| Average Diluted Shares Outstanding | 15.74M | 15.74M | 15.74M | 15.74M | 15.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |